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Abstract
Objective: To investigate the role of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic
resonance imaging (DW-MRI) when applied to the 7th TNM classification in the staging and prognosis of gastric
cancer (GC).
Methods: Between October 2009 and May 2014, a total of 89 patients with non-metastatic, biopsy proven GC
underwent 1.5T DW-MRI, and then treated with radical surgery. Tumor ADC was measured retrospectively and
compared with final histology following the 7th TNM staging (local invasion, nodal involvement and according to
the different groups — stage I, II and III). Kaplan-Meier curves were also generated. The follow-up period is
updated to May 2016.
Results: Median follow-up period was 33 months and 45/89 (51%) deaths from GC were observed. ADC was
significantly different both for local invasion and nodal involvement (P<0.001). Considering final histology as the
reference standard, a preoperative ADC cut-off of 1.80×10–3 mm2/s could distinguish between stages I and II and an
ADC value of ≤1.36×10–3 mm2/s was associated with stage III (P<0.001). Kaplan-Meier curves demonstrated that
the survival rates for the three prognostic groups were significantly different according to final histology and ADC
cut-offs (P<0.001).
Conclusions: ADC is different according to local invasion, nodal involvement and the 7th TNM stage groups
for GC, representing a potential, additional prognostic biomarker. The addition of DW-MRI could aid in the
staging and risk stratification of GC.
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Introduction
Gastric cancer (GC) is  the fourth most common cancer
worldwide,  with  poor  prognosis  and  survival  rate  for
advanced stages  (1).  Substantial  differences  exist  in  the
incidence and among different ethnic groups within the
same region (1-3). An accurate preoperative assessment is
crucial to delineate the initial approach to therapy (surgery
vs.  neoadjuvant  therapy).  Endoscopic  ultrasonography
(EUS) is the most reliable method to evaluate the depth of
invasion of primary GC, particularly for early stages (4,5).
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Multidetector computed tomography (MDCT) is a non-
invasive technique, useful to evaluate metastatic disease,
ascites, or distant nodal spread (6-8). The role of positron
emission tomography (PET) in the preoperative staging of
GC is still evolving (9).
Recently, new advances in diffusion-weighted magnetic
resonance  imaging  (DW-MRI)  have  confirmed  the
potential value of this technique for the gastrointestinal
tract  (10,11).  On  DW-MRI,  pathological  tissue  is
characterized  by  higher  signal  intensity  than  normal
structures (12,13). This technique reflects the mobility of
water  molecules  in  biological  tissues  through  the
measurement of the apparent diffusion coefficient (ADC), a
quantitative  marker  that  has  shown  great  promise  as  a
prognostic  factor  and  a  potential  biomarker  for
neoadjuvant  therapy  response  for  different  tumors,
including  GC  (14,15).  Pathological  tissues,  showing  a
higher cellularity and decreased extracellular space, result
in a restriction of water diffusion and, consequently, lower
ADC values.
The 7th staging criteria schema of the American Joint
Committee  on  Cancer  (AJCC)  and  the  Union  for
International Cancer Control (UICC) is based upon TNM
classifications  (16).  There  has  been  an  ongoing  debate
whether gastro-esophageal junction lesions (Siewert II and
III) should be staged as esophageal or gastric cancer (17),
with  interesting  results  supporting  the  latter  (18).  The
validation of the 7th TNM edition has been analyzed in
several  studies,  proving  that  the  7th  edition  is  more
accurate than the 6th edition when it comes to prognosis
(19-21).
However, there is evidence that GC in Eastern countries
(Asia  predominantly)  may  differ  biologically  from  the
Western world (22,23). Also, there is a survival advantage
for  Asian  patients  with  GC,  mostly  due  to  the  early
diagnosis (as mass screening is uncommon in the Western
world)  and  the  higher  extent  of  lymphadenectomy
performed in the Eastern world (24).
As a consequence, data on the prognostic value of the 7th
TNM classification in Western countries are scarce (25-
29). A recent multicenter study has proposed a new stage
grouping for GC, urging the scientific community to refine
the UICC/AJCC TNM classification basing on worldwide
data  (30).  Röcken  et  al.  have  also  reported  that  other
variables  (in  addition  to  T  and  N stage)  can  influence
patient survival in GC and have pointed out the need to
investigate novel  prognostic biomarkers able to reliably
differentiate different prognostic groups in patients with
GC (31). There is growing evidence supporting the use of
DW-MRI with regard to TNM staging for GC (32,33).
Hence, given both the great interest for new molecular
biomarkers (31,34) and the lack of published data from the
Western world in this regard, we evaluated the value of
ADC from DW-MRI in the staging and prognosis of GC
on a high-volume European single-center basis.
Materials and methods
This is a retrospective study of a single cohort that follows
the  Standards  for  Reporting  of  Diagnostic  Accuracy
(STARD)  guidelines,  in  accordance  with  the  World
Medical Association of Helsinki and good clinical practice
guidelines. All data were retrieved from a previous database
of a prospective study on gastro-esophageal tumors that
enrolled patients from October 2009 to May 2014. The
Medical  Ethics  Committee  of  San  Raffaele  Scientific
Institute approved the protocol, and all patients gave their
written informed consent. The follow-up period is updated
to May 2016.
Eligibility criteria
In  this  study,  the  initial  population  that  was  retrieved
comprised  173  patients.  The  patients  were  enrolled
according  to  the  following  criteria:  1)  biopsy-proven
Siewert II–III or GC; 2) visible tumor on DW-MRI; and 3)
fitness  for  surgery.  The  exclusion  criteria  were  the
following: 1) neoadjuvant therapy following initial imaging
(n=47); 2) poor image quality (n=2); 3) no visible tumor on
DW-MRI  (n=5);  4)  stage  IV  disease  (n=24);  or  5)  no
surgical data available, for comorbidities (n=2) or because
patients were treated at other institutions (n=4). The final
population consisted of 89 patients who underwent surgery.
Study design
The extent of surgical resection was carried out according
to  the  Japanese  Gastric  Cancer  Association  (JGCA)
guidelines (35). The final diagnosis of GC was assessed by
histopathological  examination  of  resected  specimens,
according to the 7th TNM edition (16).
DW-MRI protocol and evaluation
All patients were scanned on the same 1.5T MR system
(Achieva, Philips Medical Systems, Best, The Netherlands)
using a five-channel phased-array cardiac coil positioned
according to tumor location, with cardiac and respiratory
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triggering. Before the start of the examination, patients
were  invited  to  drink  500 mL of  water  and Ferumoxsil
(Lumirem®; Guerbet, Roissy CdG Cedex, France) in order
to distend the gastric walls; an intramuscular injection of
scopolamine-butylbromide  (20  mg,  Buscopan®,
Boehringer Ingelheim GmbH, Ingelheim, Germany) was
also  administered  after  patient  positioning,  in  order  to
minimize intestinal peristalsis.
The protocol study was performed according to some
previous studies (13,15). For the sake of completeness, it is
important to stress that we performed a multiplanar T2-
weighted study, followed by a DW-MRI protocol (using b
values of 0 and 600 s/mm2) and a dynamic T1-weighted
study (DCE) during intravenous injection of 0.1 mL/kg of
body weight of gadobutrol (Gadovist®, 1 mmol/mL; Bayer
Schering Pharma, Berlin, Germany).
Image analysis
Two experienced radiologists (FG and FDC with 7 and
more  than  20  years  of  experience  in  abdominal  MRI,
respectively)  who  were  privy  only  to  tumor  location
reviewed independently all DW-MRI scans. Specifically,
they were blinded to histopathological results (including
TNM  staging)  and  patients’  outcome.  Definitions  of
imaging characteristics of GC on DW-MRI were based on
previous studies (36).
Image  quality  was  sufficient  to  evaluate  tumor  ADC
values  in  all  patients.  Quantitative  measurements  were
obtained tracing a small region of interest (ROI) on the
ADC map, so as to minimize partial volume effects. During
ROI  placement,  readers  made  also  reference  to  T2-
weighted, DW-MRI and DCE sequences to identify the
lesion (Figure 1).
Statistical analysis
Continuous variables were summarized by their median
values and interquartile  range (IQR, 1st  quartile  to 3rd
quartile); categorical variables were summarized by means
of frequencies and percentages.
Inter-observer consensus and agreement in measuring
ADC  values  were  evaluated  by  means  of  Spearman’s
correlation coefficient and intraclass correlation coefficient
(ICC),  and  95%  confidence  intervals  (95%  CI)  were
evaluated  by  bootstrap,  with  adjusted  percentile.
Differences  between  groups  were  verified  by  Mann-
Whitney U test statistics.
In order to classify the population into three classes (T
stage, N stage and according to the prognostic groups of
TNM stage, respectively), two optimal cut-off sets were
identified  fitting  a  conditional  inference  tree  model
constrained  to  three  leaves.  In  the  model,  we  applied
recursive partitioning based on conditional permutation
tests.
Furthermore, at each step, P values were adjusted for
multiplicity by Benjamini and Yekutieli procedure and we
assessed  the  overall  accuracy  in  order  to  stratify  the
population  correctly  (37).  To  this  aim,  sensitivity,
specificity,  positive  and  negative  predictive  values  and
accuracy  were  fitted  by  means  of  leave-one-out  cross-
validation.
Survival curves were fitted by means of Kaplan-Meier
estimator and Log-rank test was used to verify differences
between  curves.  We  fitted  a  spline  surface  to  give  a
graphical overlook of the relationships of ADC as function
of both T and N stages (38).
All  P values were computed by means of permutation
methods, to avoid distributional assumptions or asymptotic
approximations. Statistical analyses were performed using




Baseline characteristics of the 89 patients included in this
study are shown in Table 1. The median age of the total
 
Figure 1 Tumor of the gastric antrum in a 69-year-old woman
(final  histology:  adenocarcinoma, intestinal  type,  T1bN1).  (A)
Coronal T2 weighted sequence; (B) axial T2 weighted sequence;
(C)  dynamic  contrast-enhanced study;  (D)  diffusion-weighted
imaging; (E) corresponding apparent diffusion coefficient (ADC)
map;  lesion  ADC  from  the  region  of  interest  was  1.63×10–3
mm2/s.
120 Giganti et al. DWI and gastric cancer: the role of ADC
© Chinese Journal of Cancer Research. All rights reserved. www.cjcrcn.org Chin J Cancer Res 2017;29(2):118-126
population was 71 years  (IQR: 65.86–77.77 years).  The
median interval time between DW-MRI and surgery was 9
d (IQR: 4–23 d).
DW-MRI analysis
ADC  measurements  had  a  very  good  inter-observer
reproducibility (Spearman’s rho=0.92, 95% CI, 0.88–0.95;
ICC=0.92,  95%  CI,  0.88–0.94).  Given  the  high  inter-
reader reproducibility, the measurements were averaged
between the two observers and used for the subsequent
analyses. Tables 2 and 3 show the median ADC values in
the different groups at final histology for T and N stage,
respectively. Figure 2  shows the median ADC values for
each stage in the three prognostic groups (stages I, II and
III). Data in parentheses represent the number of patients
for each group, as a function of histology. Table 4 shows the
median  ADC  values  when  patients  were  considered
according to the prognostic groups based on TNM staging
at histology.






　Siewert II 6 (7)













　N1 (<7 nodes) 15 (17)
　N2 (7–14 nodes) 20 (22)
　N3 (>14 nodes) 24 (27)
Histology
　Adenocarcinoma 62 (70)
　Signet-ring cell 26 (29)
　Lymphoepithelial carcinoma 1 (1)
Lauren classification
　Intestinal type 53 (60)




　Subtotal gastrectomy 52 (58)
　Total gastrectomy 32 (36)
Table 2 ADC values (×10–3 mm2/s) in the different subgroups at
final histology for T stage
T stage Median ADC (IQR) P
T1 1.91 (1.59–2.09)
T2 1.60 (1.53–1.84) 0.105a
T3 1.33 (1.11–1.48) <0.001b
T4a 1.22 (1.08–1.32) 0.103c
T4b 1.04 (0.83–1.26) 0.875d
T1+T2+T3 1.57 (1.37–1.89)
T4a+T4b 1.22 (1.07–1.32) <0.001e
ADC, apparent diffusion coefficient; IQR, interquartile range; a,
T1  vs.  T2;  b,  T2  vs.  T3;  c,  T3  vs.  T4a;  d,  T4a  vs.  T4b;  e,
T1+T2+T3 vs. T4a+T4b.
Table 3 ADC values (×10–3 mm2/s) in the different subgroups at
final histology for N stage
N stage Median ADC (IQR) P
N0 1.81 (1.50–1.96)
N1 1.46 (1.32–1.63) 0.004a
N2 1.37 (1.18–1.57) 0.222b
N3 1.12 (1.02–1.25) 0.003c
N1+N2+N3 1.30 (1.11–1.48) <0.001d
ADC, apparent diffusion coefficient; IQR, interquartile range; a,
N0 vs. N1; b, N1 vs. N2; c, N2 vs. N3; d, N0 vs. N1+N2+N3.
 
Figure  2  Median  ADC values  (×10–3  mm2/s)  in  the  different
groups when staged according to the three prognostic  groups
based  on  the  7th  TNM  classification.  Data  in  parentheses
represent  the number of  patients  for  each group according to
histology.
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Overall survival
The  median  follow-up  period  was  33  (IQR:  14–62.40)
months. There were 45/89 (51%) deaths, all related to GC;
specifically 4 (9%) events occurred for stage I, 8 (18%) for
stage II  and 33 (73%) for  stage III,  based on histology.
Survival  time  at  60  months  (5  years)  was  84%  (IQR:
71%–100%) for stage I, 61% (IQR: 43%–87%) for stage
II, and 23% (IQR: 13%–41%) for stage III.
Using final  histology as  the standard of  reference,  an
ADC value of ≤1.36×10–3 mm2/s could predict a negative
prognosis, enabling to differentiate stage III from stage I–II
patients  (P<0.001).  Of  note,  the  additional  cut-off  of
1.80×10–3  mm2/s  could significantly divide stage I  from
stage II patients (P<0.001) (Figure 3).
After  cross  validation  of  our  model,  we  obtained  the
following results for T stage (sensitivity: 62%; specificity:
88%; positive predictive value: 72%; negative predictive
value: 82%; accuracy: 79%) and N stage (sensitivity: 78%;
specificity: 68%; positive predictive value: 86%; negative
predictive  value:  55%;  accuracy:  75%).  The  overall
accuracy of our model was 79%.
Survival  time  for  patients  with  an  ADC  ≤1.36×10–3
mm2/s  (stage  III)  was  significantly  lower  compared  to
patients with an ADC superior to this cut-off (stages I–II).
Survival time for patients with an ADC >1.80×10–3 mm2/s
(stage I) was significantly higher than that of patients with
ADC values ranging from 1.36 to 1.80×10–3 mm2/s (stage
II).
These  results  were  also  confirmed  by  Kaplan-Meier
curves  analysis,  and  the  survival  rates  for  the  three
prognostic groups, according to the aforementioned cut-
offs  and  to  final  histology,  are  presented  in  Figure  4
(P<0.001).
Figure 5 is a graphical depiction of the aforementioned
Table 4 ADC values (×10–3  mm2/s) for each stage in the three
prognostic groups according to the 7th TNM classification
TNM stage Median ADC (IQR) P
Stage I 1.90 (1.62–2.04)
Stage II 1.51 (1.46–1.65) 0.001a
Stage III 1.22 (1.06–1.32) <0.001b
ADC, apparent diffusion coefficient; IQR, interquartile range; a,
stage I vs. II; b, stage II vs. III.
 
Figure 3 Tree plot showing the ADC values used to stratify the population into prognostic groups according to the 7th TNM edition.
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findings, in accordance with the ADC values emerged from
this study.
Discussion
Currently, TNM classification is mainly used on a routine
basis for tailoring oncologic treatment of patients affected
by  cancer.  Our  findings  support  the  use  of  a  new
prognostic biomarker in relation to TNM staging.  The
inclusion  of  ADC  into  the  TNM  classification  as  an
efficient, prognostic tool has yet to be demonstrated.
Some studies have previously determined the ability of
DW-MRI to detect,  stage and assess tumor response in
oncology (32,33,39,40). Liu et al. showed that ADC of GC
correlates inversely with T and N stage (33). Similarly, we
found that ADC was significantly different according to the
presence or absence of local invasion (T1–3 vs. T4a–b) and
nodal involvement (N0 vs. N+). We also found a significant
difference in ADC values between the groups N0–N1 and
N2–N3, respectively.
We believe  that  this  study  adds  to  current  literature
suggesting that ADC could reliably stratify patients into
the three TNM groups according to our proposed cut-offs.
The median ADC was significantly different in the three
classes, showing an inverse trend (i.e. lower ADC values
were related to higher TNM stages). This supports the idea
that more aggressive tumors have a higher cellularity and,
therefore, a more restricted diffusion of water molecules.
From a clinical point of view, this is also supported by
the cumulative survival rates shown in Figure 4, as Kaplan-
Meier curves demonstrated that the survival rates for the
three  prognostic  groups  were  significantly  different,
according to  the  above-mentioned cut-offs  and to  final
histology.  The  separation  of  survival  curves  at  each
respective stage was similar at both analyses. This is a major
finding  of  our  study  when  compared  with  previous
literature, and supports the idea that a stratification using
our cut-offs could reflect the natural history of untreated,
resectable GC in terms of survival.
We previously reported that ADC≤1.5×10–3  mm2/s  is
associated with a negative prognosis in GC (15). Our study
compares  favorably  with  this  result,  as  T1,  T2 and N0
tumors (i.e. patients with an expected better outcome) had
median ADC values higher than this cut-off.
We also noticed an opposite trend between ADC values
and the  prognostic  groups  based on TNM at  histology
(Figure 2). As an example, the T1N0 group (stage I) had a
median ADC higher than T2N1 (stage II), and this latter
had  a  higher  median  ADC than  that  of  T3N2 patients
(stage III). This confirms that less aggressive tumors (i.e.
 
Figure 4 Kaplan-Meier curves showing the overall survival rates according to the different ADC cut-offs (×10–3 mm2/s) obtained from our
study (A) and histology (B).


























Figure 5 Level plot of the spline surface of ADC as function of T
and N stage, according to the 7th TNM edition.
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higher ADC values)  are  characterized by less  restricted
water  diffusivity,  due  to  the  less  cellularity,  and  is  also
supported  by  the  favorable  outcome  showed  in  the
prognostic groups at histology.
However, we acknowledge the main limitations of this
study. Firstly, our retrospective study has been performed
on a relatively small set of patients and in a single center.
As  such,  our  results  need  to  be  confirmed  by  other
institutions in an independent validation cohort and on
different DW-MRI systems. This need is also supported by
the fact that ethnicity impacts on survival of patients with
GC and therefore an international cohort validation could
be desirable.
Our population was solely composed of patients directly
treated  with  surgery,  as  the  aim  of  this  study  was  to
investigate the relationship between ADC and TNM for
untreated,  resectable GC. As such,  patients  undergoing
neoadjuvant therapy were deliberately excluded from this
study, in order to avoid any potential biological change that
might affect pathological staging of the resected specimen
and ADC calculations.
Indeed, there is growing evidence that ADC values can
vary after neoadjuvant therapy in GC, due to the cytotoxic
effects of the treatment (e.g. necrosis or fibrosis) (12,13,15).
Consequently,  one of  our future aims is  to conduct a
similar study on patients treated with neoadjuvant therapy,
analyzing ADC variations before and after treatment. This
could  also  represent  an  additional  tool  to  help  in  the
assessment of  a  separate TNM classification performed
after neoadjuvant therapy (i.e. a new “yp” staging system
that  takes  into  account  other  variables  in  addition  to
clinical  and  pathological  data),  as  already  suggested  by
other authors (30,34).
Finally,  we  recognize  that  EUS  and  MDCT  play  a
crucial role in the preoperative staging of GC and the lack
of  comparison between the three  techniques  is  another
limitation  of  this  study.  However,  the  purpose  of  the
present report was to investigate the role of  ADC from
DW-MRI  as  a  sole  biomarker  in  the  staging  and  risk-
stratification of GC, and we deliberately focused on DW-
MRI findings.
Having said that, one of our future research plans could
be  to  conduct  a  prospective  comparison between DW-
MRI, MDCT and EUS in the staging of GC, using ADC
as an additional tool to increase the performance of MRI
when compared to MDCT and EUS.
Although  our  results  are  based  on  a  relatively  small
sample size, we believe they add to the growing evidence
that  the  application  of  DW-MRI in  GC could  aid  risk
stratification. Given the high imbalance between Asian and
Western studies on GC, this is the largest series of patients
with  this  disease  assessed  by  DW-MRI in  the  Western
world so far; of note, the same b values of 0 and 600 s/mm2
have been used in other centers to evaluate the accuracy of
DW-MRI in assessing inflammatory bowel diseases (10).
This  supports  the  idea  that  the  protocol  of  this  study
reflects the best compromise between signal-to-noise ratio
and  lesion  detection  sensitivity  for  the  gastrointestinal
tract.  Also,  this  protocol  has  already  been  used  to
investigate  the  application  of  DW-MRI  in  GC,  with
promising results (12,13,15).
Moreover,  histology  of  the  resected  specimens
(considered as the reference standard) was available for all
patients and the two radiologists participating in this study
were  blinded to  any  other  imaging/clinical  finding and
patients’ outcome, ensuring an unbiased reading of DW-
MRI scans. The follow-up period was wide (almost 7 years)
and all causes of death were related to the clinical history of
GC. ADC calculation is a post-processing analysis that can
be  performed  even  retrospectively  by  other  centers  on
different DW-MRI systems; this could be of great value in
order to test the validity of our findings, before widespread
application in clinical practice.
Conclusions
This non-invasive, quantitative biomarker appears to be of
value in evaluating the aggressiveness of GC and can be
reliably assessed by different operators, as demonstrated by
the high inter-observer reproducibility found in our study.
The addition of DW-MRI could theoretically help in the
staging and risk stratification of GC according to the 7th
TNM edition and we hope that other centers in different
countries (i.e. with a different incidence of this disease and
using different DW-MRI systems) will investigate whether
our ADC thresholds can be applied even to their clinical
scenarios.
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